Featured Press Releases

Rehabtronics Selected by Praxis Spinal Cord Institute to Launch Prelivia Pilot

Rehabtronics Selected by Praxis Spinal Cord Institute to Launch Prelivia Pilot

Spyre Therapeutics Announces Inducement Award Grants

Spyre Therapeutics Announces Inducement Award Grants

  • 04 Jan 2025

Spyre Therapeutics, Inc. a clinical-stage biotechnology company utilizing best-in-class antibody...

Eisai submitted a rolling sBLA to the U.S. FDA for LEQEMBI® IQLIK™ as a subcutaneous starting dose to treat early Alzheimer’s, under Fast Track status

Eisai submitted a rolling sBLA to the U.S. FDA for LEQEMBI® IQLIK™ as a subcutaneous starting dose to treat early Alzheimer’s, under Fast Track status

ZEISS Unveils AI-Powered Research Data Platform in Collaboration with Boehringer Ingelheim to Advance the Future of Personalized Eye Care

ZEISS Unveils AI-Powered Research Data Platform in Collaboration with Boehringer Ingelheim to Advance the Future of Personalized Eye Care

ADARx doses first patient in Phase 3 STOP-HAE trial; ADX-324 receives orphan drug designation for hereditary angioedema

ADARx doses first patient in Phase 3 STOP-HAE trial; ADX-324 receives orphan drug designation for hereditary angioedema

Bruker complements fast and cost-effective IR Biotyper® hospital hygiene testing and HAI tracing with NGS reflex testing

Bruker complements fast and cost-effective IR Biotyper® hospital hygiene testing and HAI tracing with NGS reflex testing

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

  • Abbott
  • 26 Aug 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

  • Jazz Pharmaceuticals plc
  • 25 Aug 2026
European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

  • Acadia Pharmaceuticals Inc.
  • 24 Aug 2026
Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

  • Upsher-Smith Laboratories, LLC
  • 21 Aug 2026
Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

  • Dunbar Pharmaceuticals
  • 18 Aug 2026
Former DePuy Synthes U.S. President Joins Peptilogics Board

Former DePuy Synthes U.S. President Joins Peptilogics Board

  • Peptilogics
  • 18 Aug 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.